You are here
Home > World > 3 Growth Stocks to Buy and Hold for 25 Years

3 Growth Stocks to Buy and Hold for 25 Years

Don’t let NV5’s valuation — 34 times adjusted earnings for 2017 — scare you away. With a market cap of only $613 million, current sales making up a tiny sliver of its addressable market, and wonderful growth prospects, NV5 is an ideal little-known growth stock to buy today, and own for decades to come.

Lace up for the long haul

Demitri Kalogeropoulos (Nike): For long-term investment ideas, it pays to favor companies that pair dominant market positions with valuable global brands. Nike has these two qualities in spades.

Sure, the footwear giant is struggling through a period of slowing sales growth and reduced profitability. Yet it has navigated many such slumps in the past, and its leadership spot in the industry should help it recover nicely as this one ends, too.

A man holds a soccer ball in front of a Chinese flag.A man holds a soccer ball in front of a Chinese flag.

View photos

A man holds a soccer ball in front of a Chinese flag.

China is emerging as a massive sports market. Image source: Getty Images.

Looking further out, Nike has a massive opportunity in international markets, especially one in China that’s projected to grow to many multiples of that in the U.S. by 2030. I’d expect Nike’s U.S. business to churn out higher earnings, too, as the company favors direct sales of its products over warehouse sales to its traditional retailing partners. This direct-to-consumer business is roughly twice as profitable, and so it’s good news to see metrics like the 18% growth Nike recently booked in its online segment.

Nike’s long-term results will depend on its ability to continuously raise the bar on innovative footwear and apparel products. That’s a challenge the retailer is used to meeting, though, and the prize should only get bigger as more consumers embrace the sporting lifestyle over the next quarter-century.

Buy the fear

George Budwell (Celgene Corporation): Shares of the blue chip biotech Celgene have steadily been losing ground this year, thanks to a series of clinical and regulatory setbacks in its all-important immunology franchise. The biotech’s experimental Crohn’s disease drug, GED-0301, missed the mark in a late-stage study. And not long afterwards, the Food and Drug Administration also hit the company with a refusal-to-file notification for its high-profile multiple sclerosis drug candidate ozanimod.

Why are these setbacks such a big deal? Celgene has been working toward lessening its dependence on the blockbuster blood cancer drug Revlimid for growth, by investing heavily in its late-stage pipeline. So with GED-0301 an outright failure, and ozanimod’s commercial launch delayed, the company may have to walk back its longer-term revenue forecasts even further later this year.

A well plate with samples, held in latex-gloved handsA well plate with samples, held in latex-gloved hands

View photos

A well plate with samples, held in latex-gloved hands

Image source: Getty Images.

While these problems within Celgene’s immunology pipeline are indeed noteworthy, a more global view shows that the company is still in excellent shape. And that’s why this top biotech is arguably worth buying and holding for the duration.

Celgene remains the industry leader in hematology by a wide margin, and its collaborations with cutting-edge gene-therapy companies like bluebird bio should keep it in the catbird seat in this high-growth market for the foreseeable future.

So this recent spate of bad luck should probably be viewed more as a bump in the road, instead of an existential crisis. After all, Celgene’s robust clinical pipeline has the firepower to overcome even these unfortunate events.

More From The Motley Fool

John Mackey, CEO of Whole Foods Market, an AMZN subsidiary, is a member of The Motley Fool’s board of directors. Teresa Kersten is an employee of LinkedIn and is a member of The Motley Fool’s board of directors; LinkedIn is owned by Microsoft. Demitrios Kalogeropoulos owns shares of Nike. George Budwell has no position in any of the stocks mentioned. Jason Hall owns shares of AMZN, Coca-Cola, and NV5 Global. The Motley Fool owns shares of and recommends AMZN, bluebird bio, Celgene, and Nike. The Motley Fool owns shares of NV5 Global. The Motley Fool has a disclosure policy.



Similar Posts

Web Design BangladeshBangladesh Online Market